99er久久国产精品不卡,BD在线播放国产精品,久久精品国产亚洲AAA

      <code id="xrstt"></code>
    1. <code id="xrstt"></code>
        <center id="xrstt"></center>

        <object id="xrstt"></object>

        Since its inception in 2013, Pulnovo Medical has insisted on the importance of clinical value and has been committed to creating a global OTM innovation platform with its globally leading original technology. With more than 45 Chinese and international invention patents, we have developed a range of world-first products, entered the Green Channel of CFDA for innovative medical devices, and obtained CE quality system certification. In February 2021, we were granted the FDA breakthrough device designation for our original product — a radiofrequency ablation catheter. Insisting on innovation and aiming to improve patient recovery, we have, in a short time, become a leader in the interventional therapy of pulmonary arterial hypertension and will walk together with patients toward a better future with the support of our strong research and development capabilities.

        Investor Relations
        About PADN

        Pulmonary hypertension (PH) is a group of pathophysiological syndromes characterized by increased pulmonary artery pressure (≥25mmHg at rest) and pulmonary vascular resistance (≥2.5Woodunits at rest) caused by different etiologies, which eventually lead to the right heart Increased load, right heart failure and sudden death. According to the World Health Organization, PH is divided into 5 categories. Pulmonary arterial hypertension (PAH) is currently classified as the first category of PH. The initial manifestations including dyspnea, fatigue, chest pain, dizziness, fainting, hemoptysis, palpitations, and progressive decline in activity endurance, which eventually leads to complications such as right heart failure, lung infection, pulmonary embolism, sudden death, and syncope.

        The pathological changes of PH include pulmonary vasoconstriction, intimal hyperplasia and remodeling, and thrombosis in the body. The pathogenesis is extremely complex, and many linkages are still unclear. Global scientists have never stopped researches on the treatment of PH, but in view of the ambiguity and complexity of the pathogenesis, there is still no breakthrough in the treatment of PH.

        At present, drug treatment is extremely expensive and the prognosis is comparatively poor. The cost of single-drug treatment is as high as 50,000to 70,000 dollars/year, brings a weighing burden to patients and society. Other non-pharmacological methods include transatrial septal fistula or lung transplantation, etc., which also have unsolvable problems such as high mortality and lack of donors.

        Products and Solutions
        Pulmonary hypertension is a group of pathophysiological syndromes characterized by increased pulmonary artery pressure and pulmonary vascular resistance caused by different etiologies, which eventually lead to increased right heart load, right heart failure and sudden death. Domestic and international scientists have never stopped research on the treatment of PH, but in view of the ambiguity and complexity of the pathogenesis, there is still no breakthrough in the treatment of PH. The current drug treatment is way too expensive and the prognosis is compartively poor. Other non-pharmacological methods include transatrial septal fistula or lung transplantation, etc., which also have unsolvable problems such as high mortality and lack of donors.
        • PADN Series
          Multipolar Synchronous Pulmonary Artery Radiofrequency Ablation Catheter
        Milestones
        2022
        May
        Establish Pulmonary Hypertension Care Alliance with CDQI
        June
        Rated as "Top100 Medical Device Companies "
        Rated as “TOP10 Best-Performing Companies in Value field for Minimally Invasive Intervention”
        Rated as “Top 50 Innovative Biotech Companies”
        Dr. Krishna Sudhir Joins Scientific Advisory Board
        2021
        Feb
        PADN ? has been granted designation as a FDA Breakthrough Device
        June
        PADN-CFDA clinical trial, the world’s first pulmonary hypertension treatment device RCT study, has completed all patients enrollment
        Aug
        Succesfully raised millions of dollars through OrbiMed Healthcare Fund Management, Cenova Capital, Lilly Asia Ventures(LAV), and GaoRong
        Sep
        Shanghai office opened
        Expanded wuxi office
        Passed MDR CE Certification
        Nov
        In TCT, Prof. Gregg W. Stone announced that he will lead the global PADN multicenter clinical trial
        dec
        PADN-CFDA clinical trial carried out all patients' follow-ups
        2020
        May
        Started research and development of the cold salt water instrument system for the control circle
        2019
        Nov
        Obtained the Japanese Invention Patent
        Jun
        Obtained the Russian Invention Patent
        Mar
        Obtained the European Invention Patent
        2018
        Jun
        Became the Key Medical Device Project in Wuxi City
        Jan
        Carried out multi-center, randomized, blinded, sham operation clinical trials and completed the first case enrollment
        2017
        Dec
        Pulmonary hypertension interventional products obtained the National Innovative Medical Device approval
        Sept
        Obtained TüV SüD South Germany ISO13485 system certification
        Mar
        Obtained the PADN ? series product registration inspection report
        2016
        Dec
        Obtained the Japanese Invention Patent
        Jul
        Obtained the Korean Invention Patent
        Jun
        Obtained the Russian Invention Patent
        2015
        Dec
        Obtained the China National Invention Patent
        Oct
        Completed the detailed design of special interventions for pulmonary hypertension and achieved the ground-breaking breakthrough
        Jan
        Established and operated a quality management system in accordance with YY 0287/ISO 13485
        2014
        Jul
        Reconstruction and expansion of Wuxi 10,000-grade clean production base complete
        2013
        Sept
        Founded
        Welcome to Join Us

        Work with us.
        March into a new era of technical solutions for pulmonary hypertension.
        We are ready. Now It’s Your Turn.

        Copyright ? 2020  Pulnovo Medical    蘇ICP備2020058805號

        99er久久国产精品不卡,BD在线播放国产精品,久久精品国产亚洲AAA